Alexza updates on the five post-EMA approval studies for Adasuve

14 August 2014

US drugmaker Alexza Pharmaceuticals (Nasdaq: ALXA) has provided an update on its European Medicines Agency post-approval studies for its antipsychotic drug candidate Adasuve inhalation powder, pre-dispensed (Staccato loxapine).

The drug is under development for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. As part of the Adasuve approval process with the EMA, Alexza is required to conduct five post-approval studies:

a benzodiazepine interaction study - study completed and data submitted to the EMA;
a controlled study to determine Adasuve’s effect on cardiac rhythms, or a thorough QTc study, with two doses of Adasuve - study completed and data submitted to the EMA;
a clinical program designed to evaluate the safety/efficacy of Adasuve in agitated adolescent patients - the initial study in this program, a Phase I dose-ranging study, has been initiated in collaboration with Teva and the first patient dosed;
a Post-Authorization Safety Study (PASS) - study has been initiated and the first patient dosed; and
a Drug Utilization Study (DUS) - study planned to be initiated in fourth-quarter 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK